<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854203</url>
  </required_header>
  <id_info>
    <org_study_id>ChiECRCT-2013003</org_study_id>
    <nct_id>NCT01854203</nct_id>
  </id_info>
  <brief_title>Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC</brief_title>
  <acronym>NPC</acronym>
  <official_title>Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concurrent cisplatin-based chemotherapy plus radiotherapy increased the risk of
      treatment-related death and severe acute toxicity. The survival benefit of adding concurrent
      chemotherapy to intensity modulated radiation in patients with locoregionally advanced
      nasopharyngeal carcinoma is unclear. Gemcitabine plus cisplatin chemotherapy combine with
      radiotherapy was effective and well tolerated by patients with locoregionally advanced NPC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare gemcitabine plus cisplatin induction chemotherapy
      combine intensity-modulated radiotherapy with or without concurrent cisplatin in patients
      with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to reevaluate the value
      of concurrent cisplatin when 4 cycles induction chemotherapy (gemcitabine+cisplatin) and IMRT
      is used.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Failure-free survival is calculated from the date of randomization to the date of the first failure at any site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Locoregional failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>the latency to the first local failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distant failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>The latency to the first remote failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the complete response rates between the two treatment arms</measure>
    <time_frame>12 weeks after the completion of therapy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rates of toxicity</measure>
    <time_frame>3-years</time_frame>
    <description>Rates of toxicity will also be compared. Rates will be compared by the chi-square test.The Chemotherapy toxicity include thrombocytopenia, leukocytopenia , anemia, granulocytopenia,damage to hepatic function, damage to renal function,constipation, diarrhea,vomiting and rash. The radiotherapy toxicities include mucositis, radiation dermatitis,dysphagia, xerostomia, skin fibrosis, trismus, hearing loss ane cranial neuropathy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IInductive chemotherapy + concurrent cisplatin and IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inductive chemotherapy + IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inductive chemotherapy + concurrent cisplatin and IMRT</intervention_name>
    <description>Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.</description>
    <arm_group_label>IInductive chemotherapy + concurrent cisplatin and IMRT</arm_group_label>
    <other_name>Gemcitabine and cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inductive chemotherapy + IMRT</intervention_name>
    <description>Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.</description>
    <arm_group_label>Inductive chemotherapy + IMRT</arm_group_label>
    <other_name>Gemcitabine and cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed non-keratinizing (according to World
             Health Organization (WHO 2005) histologically type).

          -  A Karnofsky performance status of at least 80;

          -  Tumor staged is according to the 7th American Joint Commission on Cancer edition as
             Stage III：T1-2N2M0, T3N0-2M0 Stage IVa：T4N0-2M0 Stage IVb：Any T、N3.

          -  Adequate marrow: a WBC ≥3.5×109 l-1; a platelet count ≥100×109 l-1; and hemoglobin
             levels ≥100 g/l.

          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)
             ≤2.5×ULN, and bilirubin ≤ULN.

          -  Adequate renal function: a creatinine clearance rate of at least 60 mL/min.

          -  Patients must be informed of the investigational nature of this study and give written
             informed consent.

        Exclusion Criteria:

          -  WHO Type keratinizing squamous cell carcinoma.

          -  Age &gt;65 years or &lt;18 years.

          -  Distant metastasis,

          -  Treatment with palliative intent.

          -  Pregnancy or lactation.

          -  a history of previous radiotherapy in the nasopharyngeal region or previous
             chemotherapy.

          -  history of renal disease, unstable cardiac disease requiring treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yong Su, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janjun Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lizhi Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janjun Li, M.D.</last_name>
    <phone>+86+13829745245</phone>
    <email>lijj@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lizhi Liu, M.D.</last_name>
    <phone>+86+13660528375</phone>
    <email>liulizh@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-jun Li, MD</last_name>
      <phone>+862087343381</phone>
      <email>lijj@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jian-jun Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-zhi Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>July 28, 2013</last_update_submitted>
  <last_update_submitted_qc>July 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jian-jun Li</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Cisplatin</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>intensity-modulated radiation therapy</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

